Log in to save to my catalogue

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3099804081

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, fatal disease. Vutrisiran, a subcutaneously administered RNA interference therapeutic agent, inhibits the production of hepatic transthyretin.
In this double-blind, randomized trial, we assigned patients with ATTR-CM in a 1:1 ratio to receive vutrisiran (25 mg) or placebo...

Alternative Titles

Full title

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_3099804081

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3099804081

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2409134

How to access this item